Charles River Laboratories International (NYSE:CRL) Rating Increased to Neutral at Redburn Atlantic

Redburn Atlantic upgraded shares of Charles River Laboratories International (NYSE:CRL) from a sell rating to a neutral rating in a report published on Monday, MarketBeat reports. Redburn Atlantic currently has $188.00 price target on the medical research company’s stock.

A number of other equities research analysts also recently commented on CRL. JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. TD Cowen lifted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. UBS Group reaffirmed a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. The Goldman Sachs Group cut their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Finally, Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $198.36.

Charles River Laboratories International Price Performance

Shares of CRL opened at $163.62 on Monday. The company has a market capitalization of $8.37 billion, a P/E ratio of 1,090.80, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $170.50 and a 200 day moving average of $186.58. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the previous year, the firm posted $2.46 EPS. The firm’s revenue was down 1.1% on a year-over-year basis. As a group, equities research analysts anticipate that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds have recently added to or reduced their stakes in CRL. Virtu Financial LLC purchased a new position in shares of Charles River Laboratories International during the third quarter worth approximately $601,000. JPMorgan Chase & Co. increased its position in shares of Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after acquiring an additional 85,759 shares during the period. State Street Corp increased its position in shares of Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Charles River Laboratories International by 3.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company’s stock worth $22,060,000 after acquiring an additional 3,714 shares during the period. Finally, Janus Henderson Group PLC increased its position in shares of Charles River Laboratories International by 7.6% during the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock worth $9,064,000 after acquiring an additional 3,268 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).